One Year on ERX-315
Dallas, Texas — September 7, 2026
Etira today announced that a patient enrolled in its ongoing Phase 1 clinical trial of ERX-315 (NCT06533332) has now remained on treatment for more than one year.
The patient entered the ERX-315-101 study with advanced cancer that had progressed on prior systemic therapies. Treatment of this duration is notable in a Phase 1 study enrolling patients for whom standard therapies are no longer effective.
“Having a patient remain on ERX-315 for more than a year is an important milestone for our program,” said Ganesh V. Raj, M.D., Ph.D., Chief Medical Officer and Co-Founder of Etira. “Phase 1 trials are designed primarily to establish safety and determine appropriate dosing, but durability of treatment in a patient with advanced cancer is encouraging. We are grateful to this patient and their family for their commitment to the study, and to the investigators, nurses, and research teams who have made it possible.”
The ongoing Phase 1 dose-escalation trial is evaluating ERX-315 in patients with advanced solid tumors and continues to enroll at clinical centers in Australia.
ABOUT THE ERX-315 CLINICAL TRIAL
ERX-315-101 is a first-in-human, open-label Phase 1 dose-escalation and cohort-expansion study evaluating the safety and tolerability of ERX-315 in participants with advanced solid tumors whose cancers no longer respond to approved systemic therapies. The study is being conducted at clinical trial centers in Australia and is registered as NCT06533332.
ERX-315 is an investigational medicine and has not been approved for any use. Safety and efficacy have not been established.
ABOUT ERX-315
ERX-315 is Etira’s first-in-class small molecule designed to induce sustained and uncompensated endoplasmic reticulum stress in cancer cells, resulting in cancer cell death while preferentially sparing normal cells.
ABOUT ETIRA
Etira is a clinical-stage biopharmaceutical company headquartered in Dallas, developing first-in-class therapies for treatment-resistant cancers.
For more information, visit etira.life.
